Inovio Pharmaceuticals (INO) Posts Narrwer than Expected Q4 Loss; Revs Light
Tweet
Share
E-mailGet Alerts INO Hot Sheet
Price: $1.15 +5.50%
Financial Fact:
License fee and milestone revenue from affiliated entity: 574.6K
Today's EPS Names:
MSGM, SMID, VISL, More
Financial Fact:
License fee and milestone revenue from affiliated entity: 574.6K
Today's EPS Names:
MSGM, SMID, VISL, More
Join SI Premium – FREE
Inovio Pharmaceuticals, Inc. (AMEX: INO) reported Q4 EPS of ($0.04), $0.01 better than the analyst estimate of ($0.05). Revenue for the quarter came in at $1.6 million versus the consensus estimate of $2.1 million.
For earnings history and earnings-related data on Inovio Pharmaceuticals, Inc. (INO) click here.
For earnings history and earnings-related data on Inovio Pharmaceuticals, Inc. (INO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla to launch Cybercab in Austin this month - report
- Is Treasury selloff a major issue for stock market bulls?
- Four Tree Island Advisory calls DoubleDown $11.25 offer too low
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
